CELLINK Acquires Nanoscribe, Visikol

The CELLINK Group, a bioconvergence company focused on the application areas of bioprinting, multiomics, cell line development, and diagnostics, strengthened its position in the biophotonics space with a pair of acquisitions totaling up to $78 million. The company acquired Nanoscribe, a spinout from the Karlsruhe Institute of Technology that is developing two-photon polymerization tools, and Visikol, a contract research services company that offers 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology services to pharma and biotech companies.